-
CA Blockbuster Release: The United States Cancer Statistics Report 2023, Cancer Mortality Rate Reduced by 33
Time of Update: 2023-02-01
This time, Cancer Statistics 2023 estimates the number of new cancer cases and deaths in the United States this year, as well as a comprehensive overview of cancer occurrence based on the latest population data on cancer incidence and mortality.
-
The FDA approved an adenovirus gene therapy for the treatment of bladder cancer
Time of Update: 2022-12-30
Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said the approval provides healthcare professionals with an innovative treatment option for patients with high-risk non-muscle-invasive bladder cancer who do not respond to BCG therapy.
-
The reason why "Old Smoking Gun" does not suffer from lung cancer has been found
Time of Update: 2022-05-21
" One pack of cigarettes a day, happy like a fairy " is a realistic portrayal of many old smokers . Smoking may be for relieving anxiety and tension, for socializing to gain acceptance in the group,
-
Yuan Zhenghong's team from Fudan University reveals a new mechanism by which hepatitis B virus induces immune tolerance by regulating CD8+ T cell thymus development
Time of Update: 2022-05-01
Recently, Yuan Zhenghong's team from the Department of Pathogenic Biology and the Key Laboratory of Medical Molecular Virology, Ministry of Education/Health and Health Commission, Fudan University School of Basic Medicine, published an online publication in the Journal of Experimental Medicine entitled: Monocytic MDSCs homing to thymus contribute to age-related Research paper on CD8+ T cell tolerance of HBV .
-
Suffering from two types of cancer, how to choose a safe and effective treatment
Time of Update: 2022-03-06
The disadvantage is that patients suffer; in addition, due to the high heterogeneity of tumors, the gene mutation profiles of different parts may be different, and there may be certain errors in the use of genetic test results to guide subsequent treatment .
-
Annual inventory: a summary of consensus on popular guidelines in the digestive field in 2021
Time of Update: 2022-01-09
cn/guideline/23140 Recommended reading: After a lapse of 14 years, the British Gastroenterology Society once again released the "Irritable Bowel Syndrome" Management Guidelines | Guidelines Consensus 2021 ACG Clinical Guidelines: Upper Digestion Management of Ulcer Bleeding In May 2021, ACG issued guidelines for upper gastrointestinal ulcer hemorrhage, mainly for the initial management of patients with upper gastrointestinal bleeding (UGIB), endoscopic evaluation time, endoscopic treatment and endoscopy of UGIB caused by ulcers Provide guidance and suggestions for post-treatment management .
-
The first IL-6R monoclonal antibody in China
Time of Update: 2021-12-08
BAT1806 is a tocilizumab injection developed by Biotech in accordance with the relevant guidelines of China's NMPA, US FDA, and EU EMA biosimilars.
As tocilizumab injection's original molecular protection patent has expired, domestic and foreign pharmaceutical companies have devoted themselves to the research and development of their biosimilar drugs .
-
J Immunother Cancer: Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer
Time of Update: 2021-09-29
Recently, foreign research teams have carried out related studies to evaluate the efficacy of Pembrolizumab combined with low-dose carboplatin in the treatment of recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers .
-
Genxi Biology and Mingji Biology collaborate to develop immune cell therapy for CLDN18.2 positive solid tumors
Time of Update: 2021-08-27
2 antibody, to further develop, produce and commercialize innovative immune cell therapy, which will benefit The majority of patients with CLDN18.
2 is regarded as one of the high-quality targets for the development of immune cell therapy, with broad potential for clinical benefit .
-
The new mechanism allows the body to "pretend" to eat less to activate stronger immunity against tumors
Time of Update: 2021-08-05
Professor Guido Cromer from the Gustave Roussi Cancer Center of the University of Sacré, Paris, and Professor Tu Yi from the Department of Breast Surgery, People's Hospital of Wuhan University, are the corresponding authors of this article .
-
The study found that many young stomach cancer patients suffer from obvious diseases
Time of Update: 2021-02-16
The study found that this new, early-onset form usually grows and spreads faster, has a worse prognostic period, and is more resistant to traditional chemotherapy than stomach cancer in older adults.
-
Data on the efficacy of 7 types of tumors were first published by Theoshi/Mershadon K drug combined with lenvatini
Time of Update: 2020-11-01
during the study period, patients were given intravenously 200 mg of Pabliju monotherapy every three weeks, for a total of no more than 35 cycles (approximately two years); main research endpoints are Objective Mitigation Rate (ORR) (TNBC, Ovarian Cancer, Gastric Cancer, Colorectal Cancer (non-MSI-H/pMMR), and BTC based on RECIST v1.1 evaluation, GBM by Neuro-oncology Response Evaluation (response assessment in neuro-oncology, RANO) standard assessment, the same next) and safety, secondary endpoints include DCR, DORS, PFS and OS.
-
Apatinib has "unstoppable ambitions". The first line is as effective as sorafenib
Time of Update: 2020-10-20
To meet the difficulties, Apatini's achievements in the field of advanced hepatocellular carcinoma In 2014, Apatini's prospective, national multi-center, randomized, open, dose-exploring Phase II trials for advanced liver cancer were selected in asCO Wall, resulting in 850 mg/qd or 7 The disease control rate (DCR) of 50 mg/qd apatini is 48.57 percent and 37.25 percent, respectively, and the medium lifetime (mOS) is 9.7 months and 9.8 months, respectively, suggesting potential survival benefits in patients with advanced liver cancer.
-
Sansheng Pharmaceuticals announced the acceptance of the Beval Pearl single anti-biosimilar drug China IND
Time of Update: 2020-09-18
2015, there were 376,000 new cases of colorectal cancer and 191,000 deaths (incidence 26.6 per 100,000 people, mortality rate of 13.5 per 100,000 people) in China, according to the National Cancer Center.
-
The correction of the right, liver see - twelve-finger editing varicose bleeding analysis
Time of Update: 2020-07-27
The !---- case summary patient, a 54-year-old woman, was admitted to hospital for "blood for 1 week" a history of hepatitis B for 15 years body: liver disease face, liver pals, spider mole, the lid
